Brief: Celularity Completes Strategic Review Of 2023 Initiatives

Imugene

26/01/2023 23:28

Jan 26 (Reuters) - Celularity Inc  CELU.O :
    * CELULARITY COMPLETES STRATEGIC REVIEW OF 2023 INITIATIVES,
INCLUDING ANTICIPATED BIOMATERIALS PRODUCTION RAMP-UP AND
PIPELINE PRIORITIZATION OF NEXT-GENERATION PRODUCT CANDIDATES
    * CELULARITY INC - COMMERCIAL BIOMATERIALS BUSINESS,
DEGENERATIVE
DISEASE PROGRAMS CONTINUE TO GATHER MOMENTUM
    * CELULARITY - NOTIFIED SUBSTANTIAL PORTION OF WORKFORCE
THAT
THEIR EMPLOYMENT MAY BE IMPACTED TO ACHIEVE STRATEGIC OBJECTIVES
    * CELULARITY INC - HOPEFUL THAT THERE WILL BE NO NEED TO
SUBSTANTIALLY REDUCE ITS HEADCOUNT
    * CELULARITY INC - PLANS TO COMPLETE REQUIRED PRECLINICAL
WORK ON
ITS ECM PRODUCT CANDIDATE OVER NEXT SEVERAL MONTHS
    * CELULARITY INC - ALSO IS CONDUCTING PRECLINICAL WORK IN
KNEE
OSTEOARTHRITIS (KOA) USING ITS PLACENTA-DERIVED EXOSOMES (PEXO)
    * CELULARITY - TO CONTINUE TO PARTNER WITH IMUGENE TO
UTILIZE
NOVEL ONCARLYTICS TECHNOLOGY TO PRIME SOLID TUMOR CELLS TO
EXPRESS CD19

Source text for Eikon:  ID:nGNX1xvdDQ 
Further company coverage:  CELU.O 
 ((Reuters.Briefs@thomsonreuters.com;))